Navigation Links
Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial
Date:6/30/2008

Prescient Medical - SECRITT I Study to Evaluate Preventive Treatment of

Potentially Life Threatening Vulnerable Plaques

ROTTERDAM, Netherlands and DOYLESTOWN, Pa., June 30 /PRNewswire/ -- An interventional cardiology team led by Professor Patrick W. Serruys successfully placed a vProtect(TM) Luminal Shield in the left anterior descending (LAD) coronary artery of a 64-year-old man at Erasmus Medical Center in Rotterdam. This case marks the start of a pilot study, known as SECRITT I, designed to evaluate the vProtect(TM) Luminal Shield as a treatment for vulnerable plaques -- atherosclerotic deposits in the coronary arteries that do not produce symptoms until they rupture with potentially fatal consequences. There are more than 500,000 sudden cardiac deaths in the US, and more than 300,000 in Europe, every year. The sudden and unexpected passing of Tim Russert, host of NBC's Meet the Press, is thought to have been the result of a vulnerable plaque rupture.

The SECRITT investigators plan to place the self-expanding vProtect(TM) Luminal Shield in 15 patients with plaques identified as vulnerable by a combination of ultrasound and optical imaging techniques. These patients will be matched with 15 controls-patients who also have non-blood-flow-limiting plaques or "lesions" that have been identified as vulnerable-who will not receive the Shield. All patients are elective patients that have been referred to the cathlab for the treatment of a major lesion impairing normal cardiac function. All 30 patients will undergo follow-up diagnostic catheterizations 6 months after the initial treatment visit, at which time their lesions will be re-evaluated. This information will enable the investigators to observe whether the Shield has stabilized the target lesions.

According to Professor Patrick W. Serruys, MD, PhD, of Erasmus University, the SECRITT I trial represents the logical extension of modern cardiac medicine: "We are very good at op
'/>"/>

SOURCE Prescient Medical
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013  Sinovac Biotech Ltd. ... of biopharmaceutical products in China ... subsidiary company of Sinovac, obtained the Certificate of ... from the China State and Food Administration (CFDA) ... production plants, and its Changping filing and packaging ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 /PRNewswire/ ... destacado desarrollador y fabricante de herramientas de precisión ... y tratamiento de la enfermedad vascular periférica y ... ADVISE ( Ad enosine V asodilator ... II durante la sesión de ensayo clínico hot ...
(Date:5/23/2013)... -- Hearing health affects a man,s lifestyle, and if he ... professionally engaged, he should address any hearing loss he may ... Better Hearing Institute (BHI) is delivering to men around ... , which leads up to and includes Father,s Day. This ... June 16. To help men address their ...
Breaking Medicine Technology:Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 2Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4
... SEATTLE, Sept. 24 Cell Therapeutics, Inc. (CTI) (Nasdaq ... II study from Brown University of OPAXIO(TM) (paclitaxel poliglumex) combined ... esophageal cancer will be presented by Dr. Howard Safran in ... the International Society of Gastrointestinal Oncology in Philadelphia, Pennsylvania on ...
... September 23 As of today, 23 September,2009, the site will be ... solidarity and digital art. , For just 1 ... project, will be to save the life of a child! , ... of the project,OneDotOneLife which has two objectives. , ...
Cached Medicine Technology:OneDotOneLife.org - Saving the Lives of More Than 2 Million Children 2
(Date:5/24/2013)... Calif. (PRWEB) May 24, 2013 Western ... retained its status of “Full Accreditation” for the next ... Council on Education (COE). , “This is a magnificent ... our hard work and student outcomes,” said College of ... to express my appreciation to the faculty, staff, preceptors, ...
(Date:5/24/2013)... (HealthDay News) -- New research suggests a link ... with insomnia. Every additional hour someone with ... drop in the likelihood of moderate or high ... University of Pennsylvania. "We were surprised ... duration and suicide risk," study author, Linden Oliver, ...
(Date:5/24/2013)... GA (PRWEB) May 24, 2013 Started in ... held in Orlando. 2013 marks AMTC’s 31st anniversary. SHINE ... family, starting with supermodel Millie Lewis and her daughter, Carey ... top agents, managers, casting directors, and music professionals including the ... Arts and XP Media. They are kings of Hollywood and ...
(Date:5/24/2013)... The nation’s first trial of a ... da Vinci Surgical System concluded yesterday, Bernstein Liebhard LLP ... Court jury ruled in a 10-to-2 decision that Intuitive ... performed a da Vinci prostatectomy on a patient who ... alleged in their lawsuit that the da Vinci complications ...
(Date:5/24/2013)... Stoler believes that there is much to be learned ... That’s why he hosts “Building New York—New York ... that’s why he invited Robert Glazer, Chief Executive Officer ... specialty practice in the greater New York area, whose ... sub-specialists service communities throughout New York and New Jersey ...
Breaking Medicine News(10 mins):Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4
... speculated over the negative effects of environmental toxins for ... disrupt the normal growth and hormonal development of girls. ... zearalenone (ZEA) produced by the Fusarium fungus species, can ... to the female reproductive hormone estrogen, and are also ...
... embarking on an expanded major clinical trial involving the use ... if the combined treatment is more effective than radiation therapy ... clinical trial is part of a $9 million grant from ... study the effectiveness of gene therapy to treat prostate cancer. ...
... asks board member to seek restatement of Beth Israel ... & Wyoming director,Robert M. Melzer should apply the same ... traded companies to his role on the,board of CareGroup, ... according to labor group 1199 SEIU United,Healthcare Workers East. ...
... Health Company,(Amex: FHC ) today announced that ... its operating results for the first quarter of ... February 13, 2008. The Company plans,to report its ... day., Shareholders and other interested parties may ...
... Union asks board member to seek restatement of ... 6 Charles River Laboratories,International director Stephen Chubb ... River Laboratories and other publicly traded,companies to his ... organization of,Beth Israel Deaconess Medical Center (BIDMC), according ...
... Co-Founder Todd Rosengart Offers Lifesaving Tips in the Fight ... ... data released from,the Center for Disease Control indicates that deaths resulting ... such as obesity, high blood pressure and high cholesterol remain on,the ...
Cached Medicine News:Health News:New study suggests link between environmental toxins and early onset puberty in girls 2Health News:Henry Ford Hospital expands research on gene and radiation therapy for prostate cancer 2Health News:Henry Ford Hospital expands research on gene and radiation therapy for prostate cancer 3Health News:Genesee & Wyoming Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:The Female Health Company Schedules First Quarter Conference Call for February 13, 2008 2Health News:Charles River Laboratories International Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:Vitals.com 'Goes Red' for American Heart Month 2Health News:Vitals.com 'Goes Red' for American Heart Month 3
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
... AMS 700 Series is an advanced three-part inflatable ... abdomen, a pump placed in the scrotum and ... cavernosa. It closely simulates the look and performance ... innovative penile implant technology, the AMS 700 Series ...
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
... Freedom leg bags are part ... a versatile line of leg bags, ... the varied needs of our customers. ... several sizes, and constructed of 100% ...
Medicine Products: